One name + one destination

Peptide status
by country.

Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.

Identity+Destination=Verification route
41tracked names
42country guides
3separate evidence lanes
99official source routes
Global source router

Two selections. No category shortcuts.

Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.

Status check updated to Thymosin Alpha-1 in 日本. No FDA-approved US product; exact foreign prescription products exist.

Current source route

Thymosin Alpha-1 in 日本

Direct answer / 日本

Can you buy Thymosin Alpha-1 in 日本?

No FDA-approved US product; exact foreign prescription products exist

FDA states that no product containing Thymosin Alpha-1 is approved in the United States and currently flags safety concerns for compounded products. Singapore separately registers an exact prescription-only Zadaxin product. Neither record authenticates a research vial, transfers approval between countries, or establishes seller authority, lawful import, product quality, availability, or individual suitability.

  1. 01
    Resolve the nameResearch price board
  2. 02
    Check 日本Research price board
  3. 03
    Verify the exact offerProduct, seller, and supply route must match
Identity recordNo FDA-approved US product; exact foreign prescription products exist

What Thymosin Alpha-1 resolves to

FDA states that no product containing Thymosin Alpha-1 is approved in the United States and currently flags safety concerns for compounded products. Singapore separately registers an exact prescription-only Zadaxin product. Neither record authenticates a research vial, transfers approval between countries, or establishes seller authority, lawful import, product quality, availability, or individual suitability.

Evidence lane
Research price board
Current record
2 of 3 rows in stock
Checked
Jul 23, 2026
ThymalfasinTA1Thymosin alpha 1thymosin alpha 1TA-1
Destination recordPMDAの製品単位の確認が必要

What 日本 still has to prove

日本でペプチド、ペプチド医薬品、減量薬、研究用材料を検索する人のために、PMDAの承認品目情報、電子添文、審査報告書、安全性情報を確認する手順をまとめたガイドです。一般名が一致するだけで承認製品、販売主体、供給経路まで同一と判断せず、英訳資料と最新の日本語記録の役割も分けて扱います。

Comparison mode
日本円 / PMDA承認、電子添文、安全性記録
Price coverage
公開基準を満たす国内販売者表は未掲載
Guide updated
2026年7月18日
Evidence coverageRouting records only

No compound-specific official record is attached to this exact pairing yet. That is an evidence gap, not proof of approval, prohibition, availability, or absence. Use the country guide and official product and seller routes to verify the exact offer.

Open the full country check
Result boundaryIdentity match ≠ destination approval ≠ verified seller

This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.

Direct answers

What a country check means.

The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.

01

Is BPC-157 legal in every European country?

No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.

02

Is retatrutide available as an approved medicine?

The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.

03

Does a tirzepatide record prove local availability?

No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.

Why the split matters

A matching name is only the first record.

  1. 01

    Resolve identity

    Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.

  2. 02

    Resolve destination

    Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.

  3. 03

    Resolve the exact offer

    Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.

Continue the evidence trail